Kesimpta

Ofatumumab, the active ingredient in Kesimpta, is a monoclonal antibody presented as a solution for subcutaneous injection. It is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing‑remitting MS, and active secondary progressive MS in adult patients and is administered under medical supervision.

GNH USA supplies Kesimpta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Kesimpta (ofatumumab) is a disease‑modifying therapy that targets B‑cell activity in multiple sclerosis.

Clinically isolated syndrome: reduces risk of progression to definitive multiple sclerosis. Relapsing‑remitting multiple sclerosis: lowers annual relapse rate and slows disability accumulation. Active secondary progressive multiple sclerosis: decreases relapse activity and may delay disability worsening.

The most frequently reported adverse reactions and the less common but serious events are listed below.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Upper respiratory tract infection: mild cold‑like symptoms. - Headache: transient mild to moderate headache. - Fatigue: general tiredness without specific cause. - Nausea: occasional mild nausea. - Mild infections: increased susceptibility to common infections.

Serious or Rare Side Effects: - Severe infections: bacterial, viral, or fungal infections requiring medical attention. - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection. - Anaphylaxis: severe allergic reaction with respiratory or cardiovascular compromise. - Hepatitis B reactivation: flare of chronic hepatitis B infection. - Neutropenia: low neutrophil count increasing infection risk. - Immune‑mediated disorders: autoimmune conditions such as thyroiditis.

When using Kesimpta, several safety considerations should be observed.

Infection monitoring: assess for signs of infection before and during therapy. Hepatitis B screening: test patients for hepatitis B prior to initiation. Vaccination status: update non‑live vaccines before starting treatment. Hypersensitivity: discontinue if severe allergic reaction occurs. Active severe infection: avoid initiating therapy in patients with ongoing serious infections. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kesimpta may interact with other medicines or vaccines; relevant interactions are categorized by clinical significance.

Major Interactions (Avoid): - Live vaccines: contraindicated due to immunosuppression risk. - Concurrent B‑cell depleting agents: may cause excessive immunosuppression. - Immunosuppressive chemotherapy: increased infection risk.

Moderate Interactions (Monitor Closely): - Non‑live vaccines: may have reduced efficacy; monitor immune response. - Antifungal azoles (e.g., ketoconazole): may affect drug clearance; observe for adverse effects.